Health Care Ranks as Week's Weakest Sector as XLV Drops

The exchange-traded fund Health Care Select Sector SPDR Fund (XLV) recorded the weakest weekly return among the eleven sector funds with a notable move of -2.7%, trailing the broader S&P 500 move of -0.2%. Across the field, 3 of the 11 sector funds rose this week. Equities faced broad pressure earlier in the week as surging Treasury yields and oil price volatility raised concerns about persistent inflation and additional interest rate hikes.

Breadth within health care reflected widespread selling across the entire sector. Over the five sessions, only 14.5% of the sector's S&P 500 members managed to post weekly gains. The sector's equal-weighted return was -1.9%, compared to the cap-weighted fund move of -2.7%. When equal-weighted measures hold up better than market-cap weighted funds during a down week, it demonstrates that the largest mega-cap holdings in the portfolio drove a disproportionate share of the fund's decline, while smaller constituents suffered somewhat milder pullbacks. This divergence highlights how concentration at the top of the index can amplify downside momentum when large-cap names face concentrated selling pressure.

The sector's steepest individual decline came from Incyte Corporation, which logged a weekly return of -6.9%. The biopharmaceutical stock traded lower throughout the week. Company filings and official press releases showed no corporate disclosures or regulatory announcements during the period. Meanwhile, Wall Street brokerage analysts reiterated or maintained existing ratings on the company during the week, indicating that the decline tracked broader market pressure rather than an isolated corporate setback.

In contrast to the prevailing sector weakness, McKesson Corporation led all health care holdings with a weekly return of +4.1%. McKesson generated almost all of its weekly gain in a single session after securing an agreement in principle to extend its pharmaceutical distribution contract with CVS Health through June 2032. The company also backed its fiscal earnings guidance as shares advanced, providing commercial visibility amid a down week for the broader group. The positive reaction underscored that company-specific operational catalysts could still drive gains even when macro headwinds weigh on the surrounding industry.

Over the trailing month, XLV is -3.9%, while its trailing three-month return stands at +1.5%. The fund underperformed the broader market across the five sessions as higher interest rates pressured equities across the board. The weekly decline marked a departure from the fund's positive three-month performance, illustrating how shifting rate expectations can introduce short-term volatility to sector returns without erasing longer-term gains.